Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland.
Metrics to compare | BANB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBANBPeersSector | |
---|---|---|---|---|
P/E Ratio | 33.4x | 33.0x | −0.5x | |
PEG Ratio | 4.72 | −0.68 | 0.00 | |
Price/Book | 2.9x | 4.0x | 2.6x | |
Price / LTM Sales | 6.6x | 4.6x | 3.0x | |
Upside (Analyst Target) | 38.1% | 24.5% | 56.6% | |
Fair Value Upside | Unlock | 1.1% | 10.1% | Unlock |